Published in N Engl J Med on January 28, 1999
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC | NCT02688036
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer (PICARES) | NCT03971214
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control (2008) 1.77
Pathological upstaging and treatment strategy of clinical stage I small cell lung cancer following surgery. J Thorac Dis (2017) 1.38
Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park) (2008) 1.20
Accelerated publication versus usual publication in 2 leading medical journals. CMAJ (2002) 1.20
Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw (2008) 1.18
Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS (2013) 1.16
Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer (2009) 1.15
Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett (2014) 1.14
Treatment options for small cell lung cancer - do we have more choice? Br J Cancer (2010) 1.07
Current role of surgery in small cell lung carcinoma. J Cardiothorac Surg (2009) 1.06
Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02
Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J (2013) 1.02
Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist (2010) 1.02
Small cell lung cancer: therapies and targets. Semin Oncol (2013) 1.02
Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J (2013) 1.00
Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Neurosurgery (2013) 0.99
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Int J Radiat Oncol Biol Phys (2012) 0.98
Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer. Lung (2013) 0.98
Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys (2011) 0.97
Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer (2006) 0.95
A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step toward individualized care and shared decision making. Radiother Oncol (2014) 0.95
Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res (2015) 0.94
Progress in the management of limited-stage small cell lung cancer. Cancer (2013) 0.93
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol (2009) 0.92
A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. Br J Cancer (2001) 0.91
Targeted therapies in small cell lung cancer: a review. Ther Adv Med Oncol (2010) 0.91
The development of targeted therapy in small cell lung cancer. J Thorac Dis (2013) 0.90
Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009. Thorax (2013) 0.90
Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC? Int J Clin Oncol (2011) 0.88
Quantitative analysis of tumor shrinkage due to chemotherapy and its implication for radiation treatment planning in limited-stage small-cell lung cancer. Radiat Oncol (2013) 0.87
FDG PET/CT metabolic tumour volume in small-cell lung cancer: better staging and prognostic stratification for an improved therapeutic strategy. Eur J Nucl Med Mol Imaging (2012) 0.87
Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. Int J Radiat Oncol Biol Phys (2015) 0.87
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol (2013) 0.86
Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience. Strahlenther Onkol (2011) 0.86
Assessment of respiration-induced motion and its impact on treatment outcome for lung cancer. Biomed Res Int (2013) 0.86
Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys (2012) 0.86
Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer. Int J Clin Oncol (2011) 0.86
Surgery in limited-disease small-cell lung cancer. Lung India (2012) 0.85
Role of HGF/MET axis in resistance of lung cancer to contemporary management. Transl Lung Cancer Res (2012) 0.84
Lung cancer 7: management of lung cancer in elderly patients. Thorax (2003) 0.84
Survival from lung cancer in England and Wales up to 2001. Br J Cancer (2008) 0.84
Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res (2016) 0.84
MET and Small-Cell Lung Cancer. Cancers (Basel) (2014) 0.83
Progress in treatment of small-cell lung cancer: role of CPT-11. Br J Cancer (2003) 0.83
Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival. Cancer J (2014) 0.83
The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer. Radiat Oncol (2011) 0.83
Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer. Br J Radiol (2014) 0.83
CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II. Br J Cancer (2006) 0.82
Primary small cell carcinoma of the vagina. Case Rep Obstet Gynecol (2013) 0.82
Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma. Int J Clin Oncol (2005) 0.82
A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. J Thorac Oncol (2009) 0.81
Efficacy of 3D conformal thoracic radiotherapy for extensive-stage small-cell lung cancer: A retrospective study. Exp Ther Med (2015) 0.81
Evidence based radiation oncology with existing technology. Rep Pract Oncol Radiother (2013) 0.81
Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes. Biomaterials (2015) 0.80
Staging and imaging of small cell lung cancer. Cancer Imaging (2012) 0.80
SCLC extensive disease--treatment guidance by extent or/and biology of response? Radiat Oncol (2008) 0.80
Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer. Radiat Oncol (2014) 0.80
Radiation treatment in older patients: a framework for clinical decision making. J Clin Oncol (2014) 0.80
Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC). Int J Clin Oncol (2009) 0.79
Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol (2014) 0.79
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer (2008) 0.79
Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy. Radiat Oncol (2013) 0.79
Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer. Radiat Oncol J (2013) 0.79
Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. Lung Cancer (2013) 0.79
Small-cell lung cancer: 8 years experience of a single multidisciplinary team. J Oncol (2008) 0.79
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. Br J Cancer (2003) 0.79
The efficacy of external beam radiotherapy for airway obstruction in lung cancer patients. Cancer Res Treat (2014) 0.78
Definitive chemoradiotherapy of limited-disease small cell lung cancer: Retrospective analysis of new predictive factors affecting treatment results. Oncol Lett (2011) 0.78
Current concepts in the management of small cell lung cancer. Indian J Med Res (2013) 0.78
The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer. Korean J Intern Med (2013) 0.78
Lung cancer 5: state of the art radiotherapy for lung cancer. Thorax (2003) 0.78
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol (2013) 0.78
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO Open (2016) 0.77
Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer. Clin Lung Cancer (2015) 0.77
Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma. Am J Clin Oncol (2014) 0.77
Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited-stage small-cell lung cancer? Thorac Cancer (2015) 0.77
Timing of thoracic irradiation in limited stage small-cell lung cancer: is it still a star on the rise? Radiat Oncol J (2013) 0.77
Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer. Int J Clin Exp Pathol (2014) 0.77
Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer. Thorac Cancer (2015) 0.77
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol (2016) 0.76
c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer. Transl Oncogenomics (2006) 0.76
Exploiting Gene Expression Kinetics in Conventional Radiotherapy, Hyperfractionation, and Hypofractionation for Targeted Therapy. Semin Radiat Oncol (2016) 0.76
Solitary pulmonary metastasis from prostate cancer with neuroendocrine differentiation: a case report and review of relevant cases from the literature. World J Surg Oncol (2015) 0.76
A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs (2006) 0.76
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Semin Oncol (2008) 0.75
Lung cancer. BMJ Clin Evid (2009) 0.75
Found in translation: Integrating laboratory and clinical oncology research. Biomed Imaging Interv J (2008) 0.75
PET-CT guided curative conformal radiation therapy in limited stage small cell lung cancer. J Thorac Dis (2015) 0.75
Radiotherapy for small-cell lung cancer. N Engl J Med (1999) 0.75
Small Cell Carcinoma of the Gallbladder: Case Report and Comprehensive Analysis of Published Cases. J Oncol (2015) 0.75
Chemotherapy for small cell lung cancer: a comprehensive review. Oncol Rev (2012) 0.75
Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board: (part 2 of 2 part series). Cancer Imaging (2013) 0.75
Feasibility of tomotherapy-based image-guided radiotherapy for small cell lung cancer. Front Oncol (2013) 0.75
Radiation dose is associated with prognosis of small cell lung cancer with superior vena cava syndrome. Int J Clin Exp Med (2015) 0.75
Lung cancer. BMJ Clin Evid (2010) 0.75
Treatment decisions and survival for people with small-cell lung cancer. Br J Cancer (2014) 0.75
Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data. Radiat Oncol (2015) 0.75
Older age impacts radiotherapy-related outcomes in soft tissue sarcoma. J Surg Res (2015) 0.75
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Emerging marine diseases--climate links and anthropogenic factors. Science (1999) 10.22
A roadmap for graphene. Nature (2012) 8.66
The Brown and Williamson documents. Where do we go from here? JAMA (1995) 5.16
A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med (1992) 5.10
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 5.02
PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol (1998) 5.01
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med (2000) 4.54
Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol (1981) 4.31
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med (1992) 4.31
Excision of deoxyribose phosphate residues by DNA polymerase beta during DNA repair. Science (1995) 4.22
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst (1994) 4.21
Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol (2001) 4.13
Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR Mycobacterium tuberculosis PCR test. J Clin Microbiol (1995) 4.11
Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res (1977) 4.02
A neuronal learning rule for sub-millisecond temporal coding. Nature (1996) 3.76
The relationship between suicide risk and sexual orientation: results of a population-based study. Am J Public Health (1998) 3.75
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol (2001) 3.44
Retrovirus genomes methylated by mammalian but not bacterial methylase are non-infectious. Nature (1983) 3.43
Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med (1977) 3.38
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol (1997) 3.27
Synergy during in vitro cytotoxic allograft responses. I. Evidence for cell interaction between thymocytes and peripheral T cells. J Exp Med (1973) 3.24
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (2010) 3.21
Neural basis of alertness and cognitive performance impairments during sleepiness. I. Effects of 24 h of sleep deprivation on waking human regional brain activity. J Sleep Res (2000) 3.17
Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem (2001) 3.16
Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol (1998) 3.11
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol (2001) 3.06
CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J (1998) 3.06
The relationship between spike rate and synchrony in responses of auditory-nerve fibers to single tones. J Acoust Soc Am (1980) 3.02
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol (1991) 3.01
Virus and trinitrophenol hapten-specific T-cell-mediated cytotoxicity against H-2 incompatible target cells. J Exp Med (1976) 3.00
The brown protein of Drosophila melanogaster is similar to the white protein and to components of active transport complexes. Mol Cell Biol (1988) 2.98
Peroxiredoxin, a novel family of peroxidases. IUBMB Life (2001) 2.91
Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg (2000) 2.88
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73
Baseline findings in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study. Invest Ophthalmol Vis Sci (1998) 2.68
Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem (1998) 2.66
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst (1995) 2.64
Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel. Proc Natl Acad Sci U S A (2001) 2.62
Demography of sexual orientation in adolescents. Pediatrics (1992) 2.61
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst (1997) 2.52
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51
Papillary cystic and solid tumors of the pancreas: a pancreatic embryonic tumor? Studies of three cases and cumulative review of the world's literature. Surgery (1995) 2.50
Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46
Analysis of repeated categorical data using generalized estimating equations. Stat Med (1994) 2.44
Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. EMBO Rep (2001) 2.43
Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys (1993) 2.42
Proliferating cell nuclear antigen-dependent abasic site repair in Xenopus laevis oocytes: an alternative pathway of base excision DNA repair. Mol Cell Biol (1994) 2.42
T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice. Nature (1980) 2.39
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol (2012) 2.38
In vitro inhibition of diphtheria toxin action by ammonium salts and amines. J Bacteriol (1965) 2.38
CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol (1998) 2.31
The probability of blindness from open-angle glaucoma. Ophthalmology (1998) 2.28
[Surgical leg prolongation]. Chirurg (1971) 2.28
Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis (1998) 2.27
Effect of preemptive multimodal analgesia for arthroscopic knee ligament repair. Reg Anesth Pain Med (2001) 2.26
Influences on adolescents' decision to postpone onset of sexual intercourse: a survival analysis of virginity among youths aged 13 to 18 years. J Adolesc Health (2000) 2.25
Primary responses of human T cells to mycobacteria: a frequent set of gamma/delta T cells are stimulated by protease-resistant ligands. Eur J Immunol (1990) 2.25
Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol (2001) 2.24
Bacterial DNA causes septic shock. Nature (1997) 2.19
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 2.16
Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. Psychiatry Res (2000) 2.15
Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. Cell Immunol (1972) 2.15
Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol (1997) 2.10
Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function. Int J Radiat Oncol Biol Phys (2001) 2.10
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
Induction of cytotoxic T lymphocytes against I-region-coded determinants: in vitro evidence for a third histocompatibility locus in the mouse. J Exp Med (1975) 2.09
A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T cell receptor, the CD8 accessory molecule and preferentially uses the V delta 1 gene segment. Eur J Immunol (1991) 2.06
Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae. J Biol Chem (1993) 2.04
Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J Biol Chem (2000) 2.04
Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol (1994) 2.04
Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol (1991) 2.03
Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum. Mol Biochem Parasitol (1996) 2.02
Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. Proc Natl Acad Sci U S A (1999) 2.02
Perception and neuronal coding of subjective contours in the owl. Nat Neurosci (1999) 2.01
Identification of overlapping DNA-binding and centromere-targeting domains in the human kinetochore protein CENP-C. Mol Cell Biol (1996) 1.99
(+/-)[125Iodo] cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig. Naunyn Schmiedebergs Arch Pharmacol (1981) 1.99
Probability of filtration surgery in patients with open-angle glaucoma. Arch Ophthalmol (1999) 1.98
Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer (1998) 1.97
Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys (1991) 1.97
Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. J Control Release (2001) 1.94
Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol (2003) 1.94
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med (1986) 1.90
Cell-mediated immune response in vitro. 3. The requirement for macrophages in cytotoxic reactions against cell-bound and subcellular alloantigens. J Exp Med (1972) 1.89
The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience. Int J Radiat Oncol Biol Phys (1991) 1.88
Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst (1990) 1.86
The role of T cells in anti-herpes simplex virus immunity. I. Induction of antigen-specific cytotoxic T lymphocytes. J Immunol (1977) 1.86
Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol (2003) 1.86